DataMeds AI, Inc. (MEDS)

Nasdaq: MEDS · Wholesale-Drugs, Proprietaries & Druggists' Sundries · Tampa, FL · filing with the SEC since 2024

Full chart Alerts Compare

Grade3.1

◀ Past 2.7● Present 2.7▶ Future 4.1

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$23.3M+28.7%

Net income-$101M-1377.1%

Earnings per share$-1.43-853.3%

Operating cash flow-$10.9M-786.1%

Cash$42,571-95.9%

Debt$23.5M+0.4%

Shareholders’ equity-$12.4M-284.8%

Shares, diluted71.0M+50.2%

Return on equityn/a

The recordfrom its filings

Filings in 202670

Newest filingNov 10 · S-1/A

Annual reportMar 20, 2026

Quarterly reportAug 17, 2026

Next report due10-Q by Nov 14

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents grantedn/a

Filer category<br>Emerging growth company

Trailing twelve months to Jun 2026Revenue $8.0MNet income -$88.3MCash from operations -$13.7Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

232425

As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form S-1/A

Listing registration, amended

Open the filing on sec.gov

Nov 10, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Nov 9, 2026 · SEC EDGAR · Form DEF 14C

Information statement

Open the filing on sec.gov

Nov 5, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 26, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 20, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 16, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 13, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 9, 2026 · SEC EDGAR · Form PRE 14C

Preliminary information statement

Open the filing on sec.gov

Oct 9, 2026 · SEC EDGAR · Form S-1/A

Listing registration, amended

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

DataMeds AI, Inc. is classed by the SEC under Wholesale-Drugs, Proprietaries & Druggists' Sundries (industry code 5122), based in Tampa, FL. Product was 94% of fiscal 2025 revenue.

Newest on the record

Listing registration, amended on Nov 10. Before it, large holder notice on Nov 10.

What is due next

The 10-Q for the period to Sep 30, 2026, due by Nov 14, 2026.

About MEDS

DataMeds AI, Inc. is classed by the SEC under Wholesale-Drugs, Proprietaries & Druggists' Sundries (industry code 5122), based in Tampa, FL. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $23 million and a loss of $101 million (its filed statements).

IndustryWholesale-Drugs, Proprietaries & Druggists' Sundries

HeadquartersTampa, FL

Business modelDistribution business

ExchangeNasdaq

Filing since2024

Fiscal year endsDec 31

SEC number (CIK)2030763

Peers on fileCOSM, HKPD, ZSTK, HWH

Who runs it

Financial performance

In fiscal 2025 DataMeds AI’s revenue was $23.34 million, up 28.7% from $18.13 million the year before. It made a net loss of $101.3 million.

Annual report, filed Mar 20, 2026.

Financial statements

The grade

DataMeds AI grades 3.1 of 10 against its own industry, the 10 companies in Wholesale-Drugs, Proprietaries & Druggists' Sundries. Five of the nine metrics are read as filed and four are SI estimates, each with its reasoning.

◀ Past2.7

● Present2.7

▶ Future4.1

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton MEDS · research, not advice